-
Recent Posts
Categories
- Anesthesiology
- Avandia
- Cardiology
- Clinics
- Consumer Products
- Emergency Rooms
- Endocrinology
- Eye Care
- Family Practice
- FDA 2011
- FDA 2012
- FDA Label Change
- FDA Notice
- FDA Recall
- FDA Safety Communication
- FDA Warning
- Gastroenterology
- Healthcare Professionals
- Hematology
- Hospitals
- Infectious Disease
- Internal Medicine
- Laboratory
- multiple sclerosis (MS)
- Neurology
- OBGYN
- Oncology
- Ophthalmology
- Pain Management
- Patients
- Pediatrics
- Pharmacy
- Psychiatry
- Radiology
- Rheumatology
- Risk Manager
- Uncategorized
Tag Archives: Drug Safety Communication
Victrelis and Ritonavir Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs Drug Safety Communication
Victrelis (boceprevir) and Ritonavir-Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs: Drug Safety Communication – Drug Interactions AUDIENCE: Infectious Disease, Pharmacy ISSUE: FDA notified healthcare professionals and patients that drug interactions between the hepatitis C virus (HCV) protease inhibitor Victrelis … Continue reading
Posted in FDA 2012, FDA Notice, FDA Safety Communication, Infectious Disease, Pharmacy
Tagged drug risks, Drug Safety Communication, FDA notice, FDA warning, Human Immunodeficiency Virus (HIV), Protease Inhibitor Drugs, Victrelis (boceprevir) and Ritonavir-Boosted, Victrelis and Ritonavir Boosted Human Immunodeficiency Virus (HIV) Protease Inhibitor Drugs
Comments Off
Proton Pump Inhibitors PPIs Drug Safety Communication
Proton Pump Inhibitors (PPIs) – Drug Safety Communication: Clostridum Difficile-Associated Diarrhea (CDAD) Can be Associated With Stomach Acid Drugs AcipHex (rabeprazole sodium) Dexilant (dexlansoprazole) Nexium (esomeprazole magnesium) Omeprazole (omeprazole) Over-the-Counter (OTC) Prevacid (lansoprazole) and OTC Prevacid 24hr Prilosec (omeprazole) and … Continue reading
Posted in Consumer Products, Family Practice, FDA 2012, FDA Notice, FDA Safety Communication, FDA Warning, Gastroenterology
Tagged Aciphex, Dexilant, drug risks, Drug Safety Communication, FDA notice, FDA Safety Communication, FDA warning, Nexium, Omeprazole, Prevacid, Prilosec, Proton Pump Inhibitors PPIs, Proton Pump Inhibitors PPIs Drug Safety Communication, PRotonix, safety label changes, stomach acid reducers, Vimovo, Zegerid
Comments Off
Tysabri (natalizumab) Drug Safety Communication
Tysabri (natalizumab): Drug Safety Communication – New Risk Factor for Progressive Multifocal Leukoencephalopathy (PML) AUDIENCE: Neurology, Gastroenterology ISSUE: FDA notified healthcare profesisonals that testing positive for anti-JC virus (JCV) antibodies has been identified as a risk factor for progressive multifocal … Continue reading
Adcetris (brentuximab vedotin) Drug Safety Communication
Adcetris (brentuximab vedotin): Drug Safety Communication – Progressive Multifocal Leukoencephalopathy and Pulmonary Toxicity AUDIENCE: Oncology, Hematology, Neurology ISSUE: FDA notified healthcare professionals that two additional cases of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection that can result in … Continue reading
Posted in FDA 2011, FDA Label Change, FDA Notice, FDA Warning, Hematology, Neurology, Oncology
Tagged Adcetris, Adcetris (brentuximab vedotin) Drug Safety Communication, brentuximab vedotin, drug risks, Drug Safety Communication, FDA notice, FDA warning, Progressive Multifocal Leukoencephalopathy, Pulmonary Toxicity, safety label changes
Comments Off
Over-the-Counter (OTC) Liquid acetaminophen FDA Notice
Liquid Acetaminophen Concentration FDA Notice AUDIENCE: Pediatrics, Consumers, Pharmacy ISSUE: The FDA is informing the public that an additional concentration of liquid acetaminophen marketed for “infants” (160 mg/5 mL) is now available. This change in the concentration will affect the … Continue reading
Posted in Consumer Products, FDA 2011, FDA Notice, Pediatrics, Pharmacy
Tagged Children Medicines, Drug Safety Communication, FDA notice, Infant/Pain Reliever, Liquid acetaminophen, Little Fevers, Over-the-Counter (OTC), Over-the-Counter (OTC) Liquid acetaminophen, Pedia Care, safety label changes, Triaminic, Triaminic Infants’ Syrup Fever Reducer Pain Reliever, Tylenol
Comments Off
Eclectic Institute Dietary Supplements Goto Kola Bladderwrack Recall
Eclectic Institute Dietary Supplements: Recall – Possible Salmonella Contamination Include the products Gotu Kola (Centella Asiatica), Bladderwrack (Fucus Vesiculosus) AUDIENCE: Consumer ISSUE: Eclectic Institute is voluntarily recalling specific lots of its freeze-dried capsules containing Gotu Kola (Centella asiatica) and Bladderwrack … Continue reading
Posted in Consumer Products, FDA 2011, FDA Recall
Tagged Bladderwrack, Consumer Products, Drug Safety Communication, Eclectic Institute Dietary Supplements, FDA recall, Goto Kola, Recall
Comments Off
Gilenya (fingolimod) Drug Safety Communication
Gilenya (fingolimod): Drug Safety Communication – Safety Review of a Reported Death After the First Dose AUDIENCE: Neurology, Patients ISSUE: The FDA has received a report of a patient with multiple sclerosis (MS) who died within 24 hours of taking … Continue reading
Posted in FDA 2011, FDA Notice, multiple sclerosis (MS), Neurology
Tagged Drug Safety Communication, FDA notice, Gilenya (fingolimod), Gilenya (fingolimod) Drug Safety Communication, multiple sclerosis (MS), Neurology
Comments Off